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ABSTRACT
α9α10 Nicotinic acetylcholine receptors (nAChRs) putatively exist at different stoichiometries. We
systematically investigated the molecular determinants of α-conotoxins Vc1.1, RgIA#, and PeIA
inhibition at hypothetical stoichiometries of the human α9α10 nAChR. Our results suggest that only
Vc1.1 exhibits strong stoichiometric-dependent inhibition at the α9α10 nAChR. The hydrogen bond
between N154 of α9 and D11 of Vc1.1 at the α9(+)-α9() interface is responsible for the
stoichiometric-dependent potency of Vc1.1.
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Introduction
Nicotinic acetylcholine receptors (nAChRs) are cation-selective pentameric ligand-gated ion
channels belonging to the family of Cys-loop receptors, which also includes γ-aminobutyric acid
type A (GABAA), glycine, and serotonin (5-HT3) receptors.1 The vertebrate nAChRs are
homo/heteromeric assembles of α1-α10, β1-β4, γ, δ or ε subunits. Although the nAChRs are
generally featured in the nervous system, they are also expressed in non-neuronal cells participating
in various physiological events and they are important targets for drug design.2
The first crystal structure of any heteromeric nAChRs, the human(h) α4β2 nAChR subtype,
reveals the overall architecture consisting of a large extracellular domain (ECD), a transmembrane
domain (TMD) and an intracellular domain (ICD) (Figure 1A).3 The ligand binding site is located at
the ECD interface of two adjacent subunits, comprising of (+) (principal) and (─) (complementary)
components. For hα4β2 nAChR, the α4 subunit loops A, B and C form the (+) site, and the β2
subunit β-sheet contributes to the (─) site (Figure 1B). Five subunits of the nAChR circle a
conducting pore (Figure 1C) where a gate consisting of hydrophobic residues, such as Leu and Ile,
is located in the middle of the TMD.
Heteromeric α9α10 nAChRs play an important physiological role in mediating olivocochlear
and vestibular neurotransmission.4,5 Transcripts/protein expression of α9 and/or α10 subunits have
been reported in dorsal root ganglion neurons,6,7 adrenal medulla,8 and in other non-neuronal cells,
such as skin keratinocytes, pituitary pars tuberalis, lymphocytes, macrophages and bladder
urothelium.9–15
α9-Containing nAChRs are potential targets for the therapy of several disorders or diseases
such as ear disorders, chronic pain and pemphigus vulgaris.7,9,11,16,17 In addition, α9-containing
nAChRs are responsible for nicotine-induced transformation of normal human breast epithelial cells,
and inducible overexpression of α9-nAChR substantially increased tumor growth.18
Conotoxins derived from the venom of Conus sea snails are pharmacologically valuable
peptides with selective potency at nAChR subtypes. α-Conotoxin antagonists of α9α10 nAChR such
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as C. victoriae Vc1.1, C. regius RgIA (Figure 2), and C. generalis GeXIVA are short and
well-folded peptides with analgesic effect in rat models of neuropathic pain. 19,20 In addition, PeIA
from C. pergrandis, displays high selectivity for the α9α10 nAChR subtype.21 Similar to Vc1.1 and
RgIA, PeIA is also a potent inhibitor of N-type calcium channels via GABAB receptor activation.22
Despite their specificity at inhibiting α9α10 nAChRs, the binding site and the
stoichiometry-dependent sensitivity of each α-conotoxin are varied. The stoichiometry of rat(r)
α9α10 nAChR heterologously expressed in Xenopus laevis oocytes was initially suggested to
consist of two α9 and three α10 subunits ((α9)2(α10)3).23 Based on this stoichiometry, Vc1.1 was
postulated to bind preferentially at the α10(+)-α9(─) interface.24 However, Indurthi et al. proposed
at least two stoichiometries (see Figure 1D,E), possibly (α9)2(α10)3 and (α9)3(α10)2, with a high
Vc1.1-sensitive α9(+)-α9(─) binding site present in the (α9)3(α10)2 composition, and two low
Vc1.1-sensitive binding sites contributed by the α10(+)-α9(─) and/or α9(+)-α10(─) interfaces that
are common in both subunit arrangements.25 In contrast, RgIA exhibited no preference for the
Vc1.1-high sensitivity binding site of the α9α10 nAChR, and it was reported that RgIA has a high
affinity for the α10(+)-α9(─) interface.26
The

molecular

determinants

that

govern

the

binding

site

selectivity

and

stoichiometry-dependent sensitivity of Vc1.1, RgIA, and PeIA at α9α10 nAChR, however, remain
elusive and the activity of PeIA at different α9α10 nAChR stoichiometries is yet to be reported. In
this study, we performed comprehensive computational modeling based on the proposed high and
low Vc1.1 sensitivity binding sites in (α9)2(α10)3 and (α9)3(α10)2 stoichiometries, in combination
with mutagenesis study on hα9α10 nAChRs expressed in oocytes injected with varied α9:α10
mRNA ratios. The sequences of Vc1.1, RgIA, and PeIA are remarkably different from each other
despite their relatively potent antagonism of the α9α10 nAChR. We aim to identify residues of the
receptor and/or peptides responsible for the α9α10 nAChR binding site selectivity and sensitivity of
these peptides. This information is essential for the design of α-conotoxin analogues with improved
selectivity for a specific α9α10 nAChR stoichiometry.
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Results and discussion
Molecular dynamics simulations
Vc1.1 was postulated to inhibit α9α10 nAChR by binding at a high affinity α9(+)-α9(─) interface
and/or a low affinity α10(+)-α9(─) interface.24,25 Both Vc1.1 binding sites share a common α9
subunit (─) component, therefore, the determinants of Vc1.1 binding should be contributed by
non-conserved residues of the α9 and α10 subunit (+) components. Overall, our molecular dynamics
(MD) simulation model suggests, the binding modes of Vc1.1 at both α9(+)-α9(─) and α10(+)-α9(─)
interfaces are similar with four salt-bridges formed involving charged residues of Vc1.1 (R7, D11,
H12 and E14) and conserved residues of the hα9 and hα10 subunits (R81, R113, E197 and D201).
The R7-D201, H12-E197, D11-R81 and E14-R113 hydrogen bonds (Figure 3A,B) are consistent
with the previously proposed interaction of Vc1.1 with the α10 subunit (+) site residues.24
In addition to the interaction with R81 of the α9 subunit (─) component, D11 of Vc1.1 forms
additional hydrogen bond with a non-conserved N154 at the α9(+)-α9(─) interface (Figure 3B). In
comparison, the corresponding α10 subunit residue G154 (Figure 3A) is incapable of direct
interaction with Vc1.1. Other non-conserved α9 and α10 subunit (+) site residues at position 188
and 190 are postulated to have no contribution to the binding affinity of Vc1.1. Our model
postulates residues α9 N188 and α10 R188 are not feasibly located to interact with Vc1.1, whereas
residues α9 I190 and α10 L190 have similar side chains.
In this study, we used the R13-deleted analogue of RgIA (RgIA#) to probe its sensitivity to
different stoichiometries of α9α10 nAChRs. RgIA# has been reported to have comparable activity
to the wild-type RgIA.27,28 RgIA# has an internal salt-bridge formed between residues D5 and R7,
involved in binding at both α10(+)-α9() and to α9(+)-α9() interfaces. At both binding sites,
residues R7 and R9 of RgIA# are buried in the binding pockets forming salt-bridges with D201 and
D121 of the (+) and () components, respectively (Figure 3C,D). Similarly, the conserved aspartate
residues D201 and D121 were suggested to interact with RgIA residues R7 and R9, respectively, at
the rα10(+)-α9() interface.28 It was also proposed that R11 of RgIA interacts with E197 of the rα10
5

subunit. However, residue R11 of RgIA# is solvent exposed and flexible in our MD simulations,
and only occasionally approaching E197 of the α10 and α9 (+) components forming unstable
salt-bridges.
The DPR (Asp-Pro-Arg) motif is conserved in α-conotoxins ImI, RgIA# (or RgIA) and Vc1.1,
and essential to their binding affinities.26,29–31 However, this sequence epitope is not present in PeIA
despite its higher potency at inhibiting the hα9α10 nAChR than Vc1.1 and RgIA# (Figure 2, S1). In
PeIA, the side chain of H5 forms an internal hydrogen bond with C8 (Figure S2), which might be
essential to stabilize the secondary structure of the peptide. No remarkable differences were
observed in the binding of PeIA at the α10(+)-α9(─) and α9(+)-α9(─) interfaces. Similar to Vc1.1,
PeIA residues H12 and E14 interact with residues E197 of the (+) and R113 of the (─) components,
respectively (Figure 3E,F).
In contrast to Vc1.1, both RgIA# and PeIA do not interact with N154 of the α9 subunit (+)
component and for PeIA, an additional hydrogen bond is formed between residue N11 (D11 in
Vc1.1) and T152 of the (+) component at both binding sites. Therefore, our model suggests lack of
binding site preference between α10(+)-α9(─) and α9(+)-α9(─) for RgIA# and PeIA.
Energy calculations
Quantitative evaluation on the contribution of the principal site residues to Vc1.1, RgIA# and PeIA
binding affinity was assessed using the MMGB/SA (molecular mechanics generalized Born/surface
area) method (Figure S3). Conserved residues on both α9 and α10 subunit (+) sites such as Y95,
W151, T152, Y192, C194, C195, E197 and Y199 significantly contribute to the binding affinity of
Vc1.1, RgIA# and PeIA. Indeed, in our model the aromatic residues of the binding site form
compact van der Waals contacts with the α-helix of the α-conotoxins, and the C192-C193 disulfide
bond stacks with the C2-C8 disulfide bond of the α-conotoxins. However, for the four (+) site
non-conserved residues at positions 154, 188, 190 and 191, only residue 154 (N in α9 subunit and G
in α10 subunit) showed significant difference in the binding energy upon interaction with Vc1.1
(Figure S3 A). The side chain of α9 N154 contributes about 4 kcal/mol, whereas α10 G154 only
6

resulted in 0.19 kcal/mol Vc1.1-binding energy shift. Binding energy calculations for RgIA#
(Figure S3B) and PeIA (Figure S3C) showed minor contribution of α9 N154 and α10 G154 in the
interactions with both α-conotoxins.
RgIA was suggested to have a high affinity binding site at the rat α10(+)-α9() interface based
on the stoichiometry model of (α9)2(α10)3 nAChR.26 Our modeling studies showed comparable
RgIA# binding energy at the principal subunits of α9(+) and α10(+) hence suggesting RgIA# has no
binding preference for either α9(+)-α9() or α10(+)-α9() interfaces of the (α9)3(α10)2 nAChR.
Overall, our computational studies suggest Vc1.1 possesses binding preference for the
α9(+)-α9(─) interface than the α10(+)α9(─) interface. Binding of RgIA# and PeIA at the hα9α10
nAChR on the other hand, is less dependent on the stoichiometry. A hydrogen-bond is formed
between α9 N154 and Vc1.1 D11 at the α9(+)-α9(─) interface and most importantly, this interaction
is absent in RgIA# and PeIA binding models at the aforementioned hα9α10 nAChR site.
Electrophysiology
Injection of biased α9 to α10 subunit mRNA ratios resulted in putative (α9)3(α10)2 and (α9)2(α10)3
stoichiometries of the rα9α10 nAChRs heterologously expressed in X. laevis oocytes.25
Consequently, a high-sensitivity Vc1.1 binding site was proposed at the α9(+)-α9() interface
present only in the (α9)3(α10)2 stoichiometry, and a low–sensitivity Vc1.1 binding site contributed
by the α10(+)-α9() interface that exists in both stoichiometries. Most importantly, the
stoichiometry of the rα9α10 nAChR expressed at 1:1 (or 10:1) and 1:3 ratios of α9:α10 mRNA was
proposed to be (α9)3(α10)2/(α9)4(α10)1 and (α9)2(α10)3 nAChRs, respectively.
To validate our prediction that the hydrogen bond interaction between Vc1.1 D11-α9 and N154
is the determinant of Vc1.1 binding preference at the hα9(+)-α9() interface, residue N154 of the
hα9 subunit was mutated to the corresponding hα10 subunit G154. We determined the biological
activity of Vc1.1, RgIA#, PeIA and, analogues Vc1.1[D11N] and Vc1.1[PeIA] at heterologously
co-expressed hα9/α9[N154G] and α10 subunits in X. laevis oocytes, injected at varying mRNA
ratios.
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Concentration-response relationships for Vc1.1, RgIA# and PeIA inhibition of hα9α10 nAChR,
expressed from an α9:α10 mRNA ratio of 1:1, gave half-maximal inhibitory concentration (IC50)
values of 1.0 ± 0.1 µM (n = 10-16), 248.7 ± 19.2 nM (n = 5-6) and 22.2 ± 1.6 nM (n = 6-8),
respectively (Figure S1). Subsequent experiments were carried out using 1 μM Vc1.1, 300 nM
RgIA# and 30 nM PeIA, close to the IC50 values of the α-conotoxins at the hα9α10 nAChR.
At α9:α10 mRNA ratios of 3:1 putatively resulting in (α9)3(α10)2 and/or (α9)4(α10)1 nAChRs, 1
μM Vc1.1 inhibited ACh-evoked currents by 65.8 ± 1.8% (n = 16), respectively (Figure 4A).
However, at α9:α10 mRNA ratio of 1:3, presumably forming the (α9)2(α10)3 nAChR stoichiometry,
1 μM Vc1.1 inhibited ACh-evoked currents by 25.5 ± 1.8% (n = 15). Similarly, Vc1.1 antagonized
only ~20% of the ACh-evoked currents mediated by α9[N154G]α10 nAChRs at 1:3 (19.5 ± 1.0%, n
= 12) and 3:1 (21.8 ± 2.2%, n = 14) α9:α10 mRNA ratios (Figure 4A).
Vc1.1 concentration-response relationships for hα9α10 nAChRs expressed from biased α9:α10
ratios revealed IC50 values of 0.75 µM at 3:1 ratio compared to 3.57 µM for 1:3 ratio (Figure S3,
Table 1). N154G mutation to the hα9 subunit, however, reduced the potency of Vc1.1 with IC50’s of
11.25 µM and 17.02 µM for hα9[N154G]α10 nAChRs at 1:3 and 3:1 ratios, respectively. Injections
of higher α9 to α10 mRNA ratios resulted in greater Vc1.1 inhibition at the expressed hα9α10
nAChRs compared to injections with excess α10 mRNA, alluding to the presence of Vc1.1-high
sensitivity α9(+)-α9() site/s in the (α9)3(α10)2 or (α9)4(α10)1 configurations. By contrast,
α9[N154G]α10 nAChRs expressed from α9[N154G]:α10 ratios of 1:3 or 3:1 showed similar
sensitivity to Vc1.1 inhibition. However, compared to the wild-type receptors, the potency of Vc1.1
inhibition at α9[N154G]α10 nAChRs expressed from α9:α10 mRNA injection at ratios of 3:1 was
decreased ~23-fold whereas at 1:3 mRNA ratio the potency of Vc1.1 was reduced 3-fold. Although
the α9 subunit (+) component N154 residue is postulated to be critical for Vc1.1 high affinity
binding at the α9(+)-α9() interface, it should be noted that despite the lack of such interface at the
1:3 ratio, Vc1.1 inhibition is affected. The 3-fold reduction of Vc1.1 potency might be explained
either by the conformational effects of the mutation to the α10(+)α9(─) binding site or by the
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removal of the α9 N154 at the α9(+)α10(─) binding site.
In contrast to Vc1.1, varying the α9:α10 mRNA ratios resulted in minor sensitivity differences
of both α9α10 and α9[N154G]α10 nAChRs to RgIA# or PeIA inhibition (Figure 4B,C). The
α9[N154G] substitution only slightly affected the sensitivity of the mutant receptors to inhibition by
both peptides. In our model, the side chain of N154 is not located in close proximity to either PeIA
or RgIA#, which may explain their minimal sensitivity difference to either interfaces of α9(+)-α9(─)
or α10(+)-α9(─) formed at the different α9α10 nAChR stoichiometries. Previous mutagenesis
studies suggested that the most favourable binding site of RgIA is at the α10(+)α9(─) interface of
r(α9)2(α10)3 nAChR.26 Similar to RgIA#, PeIA showed no stoichiometric-dependent inhibition of
hα9α10 nAChRs, suggesting that both peptides showed no preferable binding to α9(+)-α9(─) versus
α10(+)-α9(─)/α9(+)-α10(─).
Vc1.1[D11N] exhibited significantly lower potency than wild-type Vc1.1 at hα9α10 nAChRs at
both 1:3 and 3:1 ratios with IC50 values of 17.54 µM (5-fold decrease) and 10.79 µM (14-fold
decrease), respectively (Table 1). On the other hand, at α9[N154G]α10 nAChRs, Vc1.1[D11N] and
Vc1.1 possess comparable inhibitory activity at both ratios. The substantially reduced inhibitory
activity of Vc1.1[D11N] compared to the wild-type Vc1.1 might be due to the removal of R81-D11
charge interaction at both α9(+)α9(─) and α10(+)α9(─) interfaces as well as disruption to the
hydrogen bond between N154 and D11 at the α9(+)α9(─) interface (Figure 3A,B). Using
thermodynamic mutant cycles,32 the coupling coefficient (Ω) gave a reciprocal of 28.57 suggesting
a relatively strong coupling between Vc1.1 D11 and α9 N154 . Additionally, the coupling energy
between Vc1.1 D11 and α9 N154 was calculated to be 1.95 kcal/mol, comparable to the hydrogen
bond energy between N-H and O (~1.9 kcal/mol),33 further demonstrating the key pairwise
interaction between Vc1.1 D11 and α9 N154.
Vc1.1[PeIA] analogue has residues S9–L15 of PeIA grafted to the corresponding region of
Vc1.1 (Figure 2) and similar to Vc1.1[D11N], Vc1.1[PeIA] has an asparagine residue at position 11.
Vc1.1[PeIA] exhibited a similar degree of inhibition at both hα9α10 and hα9[N154G]α10 nAChRs
9

expressed from mRNA injection ratios of 1:3 and 3:1. Similar to Vc1.1[D11N], Vc1.1[PeIA] had
reduced inhibitory activity at hα9α10 nAChRs compared to Vc1.1 with the potency decreased ~4
fold and ~12-fold at 1:3 and 3:1 ratios, respectively. Thus, PeIA second loop grafting to Vc1.1
resulted in a greater decrease in potency at the hα9α10 nAChR expressed from high α9:α10 mRNA
ratio. Furthermore, Vc1.1[PeIA] and Vc1.1 possess comparable IC50 at hα9[N154G]α10 nAChR (at
1:3 and 3:1 ratios). The insensitivity of Vc1.1[PeIA] to α9α10 or α9[N154G]α10 nAChRs expressed
with excess α9 (or α9[N154G]) or α10 mRNAs resulted from the replacement of the residues,
especially D11 at the second loop of Vc1.1. As shown in PeIA-α9(+)α9(─) model (Figure 3F),
residues from the second loop of PeIA form few contacts with the side chain of α9 N154. Thus,
similar to Vc1.1[D11N], Vc1.1[PeIA] shows minor activity differences between hα9α10 nAChRs
expressed from mRNA injection ratios of 1:3 and 3:1.
The decreased binding affinity of Vc1.1[D11N] and Vc1.1[PeIA] at the α9α10 nAChRs from
1:3, and 3:1 mRNA ratios is unlikely due to the peptide conformational changes. In MD simulations,
the backbone RMSD for Vc1.1[D11N] and Vc1.1[PeIA] are comparable to Vc1.1 suggesting that
the conformation of both Vc1.1 analogues is similar to the wild-type peptide (Figure S5). In
addition, the circular dichroism profiles of Vc1.1[D11N] and Vc1.1[PeIA] were similar to the
wild-type peptides, Vc1.1 and PeIA, further suggesting that sequence mutations and sequence
replacement resulted in minimal conformation perturbation (Figure S6).
Conclusion
Our computational modelling in combination with mutagenesis studies support that the
stoichiometry of the hα9α10 nAChR expressed with α9:α10 mRNA injection ratios of 1:3 and 3:1
could correspond to (α9)2(α10)3 and (α9)3(α10)2/(α9)4(α10)1 nAChRs, respectively. The
(α9)3(α10)2/(α9)4(α10)1 nAChR arrangement uniquely contains an α9(+)-α9(─) interface binding
site that is responsible for the higher sensitivity of the receptor to Vc1.1 than that of the (α9) 2(α10)3
nAChR. The non-conserved residue at position 154 of both hα9 and hα10 subunits essentially
differentiates the binding affinity of Vc1.1 to α9(+)-α9(─) and α10(+)-α9(─) interfaces. The
10

hydrogen bond formed between the side chains of α9 N154 and Vc1.1 D11 confers the specificity of
Vc1.1 at α9(+)-α9(─) interface, and is responsible for the higher sensitivity of the α9α10 nAChR
expressed with higher abundance of the α9 mRNA to Vc1.1. The α10(+)-α9(─) interface is the most
favourable Vc1.1 binding site at (α9)2(α10)3 nAChR whereas at (α9)3(α10)2/(α9)4(α10)1 nAChR, the
interface of α9(+)-α9(─) rather than α10(+)-α9(─) interface has higher affinity for Vc1.1. Despite
sharing the same disulfide-bond framework with Vc1.1, PeIA demonstrates no obvious
stoichiometry-dependent inhibition of α9α10 nAChRs and it also does not discriminate between
either α9(+)-α9(─) or α10(+)-α9(─) interfaces from our modelling studies. RgIA# exhibits no
preferential inhibitory activity at either (α9)3(α10)2 or (α9)2(α10)3 nAChRs and residues of RgIA#
have no remarkable specific pairwise interactions to the interfaces of α9(+)-α9(─) or α10(+)-α9(─).
However, we cannot exclude the possibility of the α9(+)-α9(─) as an energetically favourable
binding site of RgIA# at (α9)3(α10)2 nAChR. Instead, our study suggests that the sensitivity of both
α10(+)-α9(─) and α9(+)-α9(─) interfaces to RgIA# might be comparable. In a previous study, the
contribution of α9 and α10 subunits to complementary components of the ligand-binding site was
proposed to be non-equivalent,34 whereas we found the contribution of α9 and α10 subunits to
principal components of the ligand-binding site was non-equivalent for Vc1.1 binding but could be
equivalent for the binding of RgIA# and PeIA.
In summary, elucidation of the determinants that confer the selectivity of the α-conotoxins to
varied subunit arrangements of the hα9α10 nAChR is essential for rational design of novel
stoichiometric-selective α-conotoxin analogues. Whether different stoichiometries of hα9α10
nAChR exist in vivo is yet to be determined. Regardless, stoichiometric-selective inhibitors of
α9α10 nAChR would be useful neurochemical tools for further elucidating the functional
differences between the stoichiometries in native cells. Conversely, α9α10 nAChR antagonists that
do not discriminate between the stoichiometries, may be suitable candidates to use under conditions
where different stoichiometries exist.
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Methods
Homology modeling
Models of Vc1.1 bound h(α9)2(α10)3 and h(α9)2(α10)3 nAChRs were built using Modeller (version
9v14), as described previously.24,30 The extracellular domain sequence of the hα1, α3, α4, α6, α7, α9,
and α10 nAChR subunits were retrieved from the Uniprot database.35 Both crystal structures of
Aplysia californica AChBP (acetylcholine binding protein) in complex with α-conotoxin
PnIA[Α10L,D14K] (PDB code 2BR8), and the hα9 nAChR subunit extracellular domain (PDB
code 4D01) from the Protein Data Bank, were used as templates to build 200 models of each
α-conotoxin-nAChR complexes.36,37 Models with the lowest DOPE score were selected for further
structural refinement using molecular dynamics (MD) simulations. The structures of Vc1.1
analogues, Vc1.1[D11N] and Vc1.1[PeIA], were generated using Modeller based on the NMR
structure of Vc1.1(PDB code 2H8S).38
Molecular dynamic simulations
The protonation states of His, Asp and Glu residues at the conotoxin/nAChR complexes were
predicted using the PropKa 3.1 method.39 The models were minimized and refined using molecular
dynamics (MD) simulations performed with the Amber 16 package and ff14SB force field.40,41 The
receptor complexes were solvated in a truncated octahedral TIP3P water box containing ~10800
water molecules. Sodium ions were added to neutralize the systems. The systems were first
minimized with 3,000 steps of steepest descent and then 3,000 steps of conjugate gradient with the
solute restrained to their position by a harmonic force of 100 kcal/mol·Å2. A second minimization
was then performed but with all position restraints withdrawn. The systems were then gradually
heated up from 50 to 300 K in the NVT ensemble over 100 ps with the solute restrained to their
position using a 5 kal/mol·Å2 harmonic force potential. MD simulations were then carried out in the
NPT ensemble, and the position restraints were gradually removed over 100 ps. The production
runs were conducted over 50 ns simulation time with pressure coupling set at 1 atm and a constant
temperature of 300 K. The MD simulations used a time step of 2 fs and, all bonds involving
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hydrogen atoms were maintained to their standard length using the SHAKE algorithm.42 The
particle-mesh Ewald (PME) method was used to model long-range electrostatic interactions.43 MD
trajectories were analyzed using VMD (http://www.ks.uiuc.edu/) and molecules were drawn using
PyMol (Schrödinger, LLC).
For validation of the Vc1.1 analogue stability, 100 ns repeated MD simulations were performed
on Vc1.1[N9D] and Vc1.1[PeIA] systems respectively, using the same method as described above.
Binding energy decomposition
To quantify the binding energy contribution of these key residues in the ligand binding site, binding
energy decomposition was carried out using the MMPBSA.py script in AMBER16.44 The binding
free energy (ΔG binding) values were calculated using the following equation:
ΔGbinding = Gcomplex – Gligand – Greceptor

(1)

where the binding free energy (ΔGbinding) was determined using MMGB/SA method.45 This method
was identified in our previous study as being slightly more efficient for ranking mutational energies
based on homology models than the MMPB/SA method. Details of the MMGB/SA method on
peptide binding energy calculation was described in our previous modelling studies.30
Thermodynamic mutant cycles
The coupling coefficient (Ω) and coupling energy (ΔGcouple) was determined using equations (2)
and (3) respectively:
Ω = Ki of wild-type toxin at wild-type channel·Ki of mutant toxin at mutant channel/Ki of wild-type
toxin at mutant channel·Ki of mutant toxin at wild-type channel (2) 32
where Ki = equilibrium inhibition constant (IC50)
ΔGcouple = -RTln(Ω) (3)
where R = gas constant, T = temperature
Peptide synthesis
Procedures for solid peptide synthesis of Vc1.1 analogues were nearly the same as described
previously.24 Briefly, Vc1.1[D11N] and Vc1.1[PeIA] were assembled on rink amide
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methylbenzhydrylamine resin (Novabiochem) using solid-phase peptide synthesis with a
neutralization/2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate activation
procedure for Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. Cleavage was achieved by
treatment with 88:5:5:2 ratio of trifluoroacetic acid (TFA), phenol, water and triisopropylsilane as
scavengers, at room temperature (20−25 °C) for 2 h. TFA was evaporated at low pressure in a rotary
evaporator. Peptides were precipitated with ice-cold ether, filtered, dissolved in 50% buffer A/B
(buffer A consists of 99.95% H2O/ 0.05% TFA and buffer B consists of 90% CH3CN/10%
H2O/0.045% TFA), and lyophilized. Crude peptides were purified by RP-HPLC on a Phenomenex
C18 column, and its molecular mass was confirmed using electrospray mass spectrometry before
they were pooled and lyophilized for oxidation. The four cystines in the peptides were selectively
oxidized in two steps. In the first step the non-protected cystines were oxidized in 0.1 M NH4HCO3
(pH 8–8.5) at a concentration of 0.5 mg/ml, and stirred at room temperature overnight. In the
second step, the Acm-protected cystines were oxidized by dissolving the peptides in iodine solution
filled at concentration of 1 mg/ml, and stirred for 30 min. Ascorbic acid was then added to stop the
oxidizing reaction and the solution was stirred again until no colour was visible. After two rounds of
oxidation, peptides were purified by RP-HPLC and their mass (Figure S7) and purity (Figure S8)
were validated using electrospray-mass spectrometry (MS) and analytical RP-HPLC, respectively.
Circular dichroism (CD) study
CD spectra were performed on Jasco J-810 spectropolarimeter over the wavelength range of
250-190 nm using a 1.0 mm path length cell, a bandwidth of 1.0 nm, a response time of 2 s, and
averaging over three scans. Spectra were recorded at room temperature under nitrogen atmosphere.
Peptides were dissolved in buffer A and buffer B. The concentration of Vc1.1, Vc1.1[D11N],
Vc1.1[PeIA], and PeIA was 0.28 mM, 0.28 mM, 0.29 mM and 0.30 mM, respectively. The spectra
are expressed as molar ellipticity ([θ])·[θ] = 1000·mdeg/(l·c) where, mdeg is the raw CD data, c is
the peptide molar concentration (mM), and l is cell path length (mm).
PCR site-directed mutagenesis
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N154G mutation to the hα9 nAChR subunit in plasmid pT7TS was done using PrimeSTAR Max kit
(Takara Bio, Kusatsu, Shiga, Japan). Mutation was confirmed by DNA sequencing (Australian
Genome Research Facility, Melbourne, VIC, Australia).
In vitro cRNA synthesis
Plasmid pT7TS constructs of hα9 and hα10 nAChR subunits were linearized with XbaI restriction
enzyme (NEB, Ipswich, MA) for in vitro cRNA transcription using T7 mMessage mMachine
transcription kits (AMBION, Foster City, CA, USA).
Oocyte preparation and microinjection.
All procedures were approved by the University of Sydney Animal Ethics Committee (project
number 2016/970). Stage V-VI oocytes (Dumont’s classification; 1200-1300 μm diameter) were
obtained from Xenopus laevis, defolliculated with 1.5 mg/ml collagenase Type II (Worthington
Biochemical Corp., Lakewood, NJ) at room temperature for 1-2 h in OR-2 solution containing (in
mM) 82.5 NaCl, 2 KCl, 1 MgCl2 and 5 HEPES at pH 7.4. Oocytes were injected with 35 ng cRNA
for hα9α10 nAChR (concentration confirmed spectrophotometrically and by gel electrophoresis) at
α9:α10 subunit mRNA ratios of 1:1. 1:3 and 3:1, using glass pipettes pulled from glass capillaries
(3-000-203 GX, Drummond Scientific Co., Broomall, PA, USA). Oocytes were incubated at 18 ºC
in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2 and 5 HEPES at
pH 7.4, supplemented with 5% FBS, 50 mg/L gentamicin (GIBCO, Grand Island, NY, USA) and
10000 U/mL penicillin-streptomycin (GIBCO, Grand Island, NY, USA).
Oocyte two-electrode voltage clamp recording and data analysis.
Electrophysiological recordings were carried out 2–5 days post cRNA microinjection.
Two-electrode voltage clamp recordings of X. laevis oocytes expressing human nAChRs were
performed at room temperature (21−24 °C) using a GeneClamp 500B amplifier and pClamp9
software interface (Molecular Devices, Sunnyvale, CA, USA) at a holding potential ─80 mV.
Voltage-recording and current-injecting electrodes were pulled from GC150T-7.5 borosilicate glass
(Harvard Apparatus, Holliston, MA) and filled with 3 M KCl giving resistances of 0.3–1 MΩ.
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Oocytes were incubated in 100 µM BAPTA-AM ~3 h before recording and perfused with ND115
solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2, and 10 HEPES at pH 7.4 using a
continuous Legato 270 push/pull syringe pump perfusion system (KD Scientific, Holliston, MA,
USA) at a rate of 2 mL/min in an OPC-1 perfusion chamber of < 20 µL volume (Automate
Scientific, Berkeley, CA, USA). Due to the Ca2+ permeability of hα9α10 nAChRs, BAPTA-AM
incubation was carried out to prevent the activation of X. laevis oocyte endogenous Ca2+-activated
chloride channels.
Initially, oocytes were briefly washed with ND115 solution followed by 3 applications of
acetylcholine (ACh) at a half-maximal excitatory ACh concentration (EC50) for hα9α10 nAChRs.
Washout with bath solution was done for 3 min between ACh applications. Oocytes were incubated
with peptides for 5 min with the perfusion system turned off, followed by co-application of ACh
and peptide with flowing bath solution. All peptide solutions were prepared in ND115 + 0.1 %
bovine serum albumin. Peak current amplitudes before (ACh alone) and after (ACh + peptide)
peptide incubation were measured using Clampfit version 10.7.0.3 software (Molecular Devices,
Sunnyvale, CA, USA), where the ratio of ACh + peptide-evoked current amplitude to ACh
alone-evoked current amplitude was used to assess the activity of the peptides at hα9α10 nAChRs.
All electrophysiological data were pooled (n = 3-16) and represent means ± standard error of the
mean (SEM). Data analysis was performed using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA, USA). ACh EC50 and -conotoxin IC50 values were determined from concentration-response
relationships fitted to a non-linear regression function and reported with error of the fit. Data sets
were compared using Tukey’s test. Differences were regarded statistically significant when
p < 0.05.
Supporting Information
Activity of the α-conotoxins at the human α9α10 nAChRs is shown in Figure S1. Internal backbone
H-bond between PeIA residues H5 and C8 is shown in Figure S2. Side chain energetic contribution
to the α-conotoxin binding affinity is shown in Figure S3. Activities of the α-conotoxins at human
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α9α10 and α9[N154G]α10 nAChRs expressed from varied α9:α10 mRNA ratios are shown in
Figure S4. Structural comparison of wild-type Vc1.1 and analogues Vc1.1[D11N] and Vc1.1[PeIA]
from MD simulations are shown in Figure S5. Circular dichroism spectra of Vc1.1, Vc1.1[D11N],
Vc1.1[PeIA] and PeIA are shown in Figure S6. MS and analytical HPLC spectra of Vc1.1,
Vc1.1[D11N], Vc1.1[PeIA], PeIA and RgIA# are shown in Figure S7 and Figure S8, respectively.
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Table 1. Inhibition of h910 and h9[N154]10 expressed from α9/α9[N154G]:α10 mRNA
injection ratios of 1:3 and 3:1 by Vc1.1 and analogues.

ACh

Vc1.1

Vc1.1[D11N]

Vc1.1[PeIA]

(µM)

(µM)

(µM)

(µM)

1:3

47.42 ± 5.77

3.57 ± 0.31

17.54 ± 2.11

13.23 ± 1.80

3:1

40.00 ± 5.98

0.75 ± 0.09

10.79 ± 1.14

9.30 ± 0.86

1:3

13.12 ± 0.93

11.25 ± 1.50

10.24 ± 0.69

12.96 ± 1.89

3:1

34.28 ± 3.99

17.02 ± 3.17

8.59 ± 0.77

15.2 ± 1.34

Receptor

α9:α10

hα9α10

hα9[N154G]α10

EC50 values (mean ± error of the fit, n = 3-4) obtained from the fit of the ACh
concentration-response relationship for hα9α10 and hα9[N154G]α10 nAChRs expressed from
α9/α9[N154G]:α10 mRNA injection ratios of 1:3 and 3:1
IC50 values (mean ± error of the fit, n = 3-16) obtained from the fit of the concentration-response
relationships for the inhibition of hα9α10 and hα9[N154G]α10 nAChRs expressed from
α9/α9[N154G]:α10 mRNA injection ratios of 1:3 and 3:1 by Vc1.1, Vc1.1[D11N], and
Vc1.1[PeIA].
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Figure 1. Structures of the nAChRs. (A) Side view of the human α4β2 nAChR crystal structure
showing the extracellular (ECD) and transmembrane (TMD) domains. Two nicotine molecules
(NCT, orange) are bound to the ECD binding site (dashed frame) (PDB code: 5KXI). The α4 and β2
subunits are colored blue and grey, respectively. (B) The ligand binding site magnified (dashed
frame) comprising of loops A, B and C of the α4 subunit (principal component (+)) and β-sheet of
the β4 subunit (complementary component (─)); (C) Top view of the human α4β2 nAChR; (D,E)
Top view of the (α9)2(α10)3 nAChR and (α9)3(α10)2 nAChR homology models, respectively. The
α-conotoxin binding site is located at the cleft between the α10(+) and α9(─) components or α9(+)
and α9(─) components (orange cloud). The (+) component contributes the C-loop to the binding site,
and the (─) component contributes the β-sheet to the binding pocket. These models were built using
multiple templates, including the crystal structures of Aplysia californica AChBP (PDB code: 2BR8)
and the human α9 nAChR subunit ECD (PDB code: 4UY2).
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Figure 2: Sequence alignment and structures of the α-conotoxins. (A) Sequence alignment of
the α-conotoxin Vc1.1, PeIA, RgIA# and their analogues. There are two disulphide bonds (black
lines) linking CI and CIII, and CII and CIV, respectively. The DPR motif is highlighted using the grey
background. Vc1.1 and PeIA possess a 4/7 disulphide framework, and RgIA has a 4/3 disulphide
framework. * represents the amide group of the C-termini. (B) and (D) NMR structures of Vc1.1
(PDB code: 2H8S) and RgIA (PDB code: 2JUT), and (C) crystal structure of PeIA (PDB code:
5JME).
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Figure 3. Binding of the α-conotoxins at the human α10(+)-α9(─) and α9(+)-α9(─) interfaces.
(A,B), (C,D), and (E,F) α-Conotoxins Vc1.1, RgIA# and PeIA bound to the interfaces of
α10(+)-α9(─) (left panels) and α9(+)-α9(─) (right panels), respectively. The α10 and α9 subunits
are shown in cyan and green, respectively. Dashed lines indicate hydrogen bonds formed between
the α-conotoxins and α9α10 nAChR.
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Figure 4. Activity of the α-conotoxins at human α9α10 and α9[N154G]α10 nAChRs expressed
from varied α9:α10 mRNA ratios. Bar graphs of relative ACh-evoked current amplitude mediated
by hα9α10 and hα9[N154G]α10 nAChRs in the presence of (A) 1 μM Vc1.1, (B) 300 nM RgIA#,
and (C) 30 nM PeIA. Whole-cell hα9α10 nAChR-mediated currents at 1:3 and 3:1 ratios were
activated by 50 μM and 30 μM ACh, respectively, and hα9[N154G]α10 nAChR-mediated currents
at 1:3 and 3:1 ratios were activated by 20 μM and 30 μM ACh, respectively (close to their
respective EC50 values). ** p < 0.0001
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